Regression of Melanoma Following Intravenous Injection of Plumbagin Entrapped in Transferrin-Conjugated, Lipid–Polymer Hybrid Nanoparticles

Regression of Melanoma Following Intravenous Injection of Plumbagin Entrapped in Transferrin-Conjugated, Lipid–Polymer Hybrid Nanoparticles

Intouch Sakpakdeejaroen,1 Sukrut Somani,1 Partha Laskar,1 Margaret Mullin,2 Christine Dufès1 1Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, UK; 2College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sakpakdeejaroen I, Somani S, Laskar P, Mullin M, Dufès C
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2021
Materias:
plumbagin
transferrin
tumor targeting
lipid–polymer hybrid nanoparticles
cancer therapy
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/cf69c5bd01a64d4a8f06a17a996c54ee
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:cf69c5bd01a64d4a8f06a17a996c54ee
record_format dspace
spelling oai:doaj.org-article:cf69c5bd01a64d4a8f06a17a996c54ee2021-12-02T14:52:52ZRegression of Melanoma Following Intravenous Injection of Plumbagin Entrapped in Transferrin-Conjugated, Lipid–Polymer Hybrid Nanoparticles1178-2013https://doaj.org/article/cf69c5bd01a64d4a8f06a17a996c54ee2021-04-01T00:00:00Zhttps://www.dovepress.com/regression-of-melanoma-following-intravenous-injection-of-plumbagin-en-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Intouch Sakpakdeejaroen,1 Sukrut Somani,1 Partha Laskar,1 Margaret Mullin,2 Christine Dufès1 1Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, UK; 2College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UKCorrespondence: Christine DufèsStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, United KingdomTel +44 1415483796Fax +44 1415522562Email C.Dufes@strath.ac.ukBackground: Plumbagin, a naphthoquinone extracted from the officinal leadwort presenting promising anti-cancer properties, has its therapeutic potential limited by its inability to reach tumors in a specific way at a therapeutic concentration following systemic injection. The purpose of this study is to assess whether a novel tumor-targeted, lipid–polymer hybrid nanoparticle formulation of plumbagin would suppress the growth of B16-F10 melanoma in vitro and in vivo.Methods: Novel lipid–polymer hybrid nanoparticles entrapping plumbagin and conjugated with transferrin, whose receptors are present in abundance on many cancer cells, have been developed. Their cellular uptake, anti-proliferative and apoptosis efficacy were assessed on various cancer cell lines in vitro. Their therapeutic efficacy was evaluated in vivo after tail vein injection to mice bearing B16-F10 melanoma tumors.Results: The transferrin-bearing lipid–polymer hybrid nanoparticles loaded with plumbagin resulted in the disappearance of 40% of B16-F10 tumors and regression of 10% of the tumors following intravenous administration. They were well tolerated by the mice.Conclusion: These therapeutic effects, therefore, make transferrin-bearing lipid–polymer hybrid nanoparticles entrapping plumbagin a highly promising anti-cancer nanomedicine.Keywords: plumbagin, transferrin, tumor targeting, lipid–polymer hybrid nanoparticles, cancer therapySakpakdeejaroen ISomani SLaskar PMullin MDufès CDove Medical Pressarticleplumbagintransferrintumor targetinglipid–polymer hybrid nanoparticlescancer therapyMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 16, Pp 2615-2631 (2021)
institution DOAJ
collection DOAJ
language EN
topic plumbagin
transferrin
tumor targeting
lipid–polymer hybrid nanoparticles
cancer therapy
Medicine (General)
R5-920
spellingShingle plumbagin
transferrin
tumor targeting
lipid–polymer hybrid nanoparticles
cancer therapy
Medicine (General)
R5-920
Sakpakdeejaroen I
Somani S
Laskar P
Mullin M
Dufès C
Regression of Melanoma Following Intravenous Injection of Plumbagin Entrapped in Transferrin-Conjugated, Lipid–Polymer Hybrid Nanoparticles
description Intouch Sakpakdeejaroen,1 Sukrut Somani,1 Partha Laskar,1 Margaret Mullin,2 Christine Dufès1 1Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, UK; 2College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UKCorrespondence: Christine DufèsStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, United KingdomTel +44 1415483796Fax +44 1415522562Email C.Dufes@strath.ac.ukBackground: Plumbagin, a naphthoquinone extracted from the officinal leadwort presenting promising anti-cancer properties, has its therapeutic potential limited by its inability to reach tumors in a specific way at a therapeutic concentration following systemic injection. The purpose of this study is to assess whether a novel tumor-targeted, lipid–polymer hybrid nanoparticle formulation of plumbagin would suppress the growth of B16-F10 melanoma in vitro and in vivo.Methods: Novel lipid–polymer hybrid nanoparticles entrapping plumbagin and conjugated with transferrin, whose receptors are present in abundance on many cancer cells, have been developed. Their cellular uptake, anti-proliferative and apoptosis efficacy were assessed on various cancer cell lines in vitro. Their therapeutic efficacy was evaluated in vivo after tail vein injection to mice bearing B16-F10 melanoma tumors.Results: The transferrin-bearing lipid–polymer hybrid nanoparticles loaded with plumbagin resulted in the disappearance of 40% of B16-F10 tumors and regression of 10% of the tumors following intravenous administration. They were well tolerated by the mice.Conclusion: These therapeutic effects, therefore, make transferrin-bearing lipid–polymer hybrid nanoparticles entrapping plumbagin a highly promising anti-cancer nanomedicine.Keywords: plumbagin, transferrin, tumor targeting, lipid–polymer hybrid nanoparticles, cancer therapy
format article
author Sakpakdeejaroen I
Somani S
Laskar P
Mullin M
Dufès C
author_facet Sakpakdeejaroen I
Somani S
Laskar P
Mullin M
Dufès C
author_sort Sakpakdeejaroen I
title Regression of Melanoma Following Intravenous Injection of Plumbagin Entrapped in Transferrin-Conjugated, Lipid–Polymer Hybrid Nanoparticles
title_short Regression of Melanoma Following Intravenous Injection of Plumbagin Entrapped in Transferrin-Conjugated, Lipid–Polymer Hybrid Nanoparticles
title_full Regression of Melanoma Following Intravenous Injection of Plumbagin Entrapped in Transferrin-Conjugated, Lipid–Polymer Hybrid Nanoparticles
title_fullStr Regression of Melanoma Following Intravenous Injection of Plumbagin Entrapped in Transferrin-Conjugated, Lipid–Polymer Hybrid Nanoparticles
title_full_unstemmed Regression of Melanoma Following Intravenous Injection of Plumbagin Entrapped in Transferrin-Conjugated, Lipid–Polymer Hybrid Nanoparticles
title_sort regression of melanoma following intravenous injection of plumbagin entrapped in transferrin-conjugated, lipid–polymer hybrid nanoparticles
publisher Dove Medical Press
publishDate 2021
url https://doaj.org/article/cf69c5bd01a64d4a8f06a17a996c54ee
work_keys_str_mv AT sakpakdeejaroeni regressionofmelanomafollowingintravenousinjectionofplumbaginentrappedintransferrinconjugatedlipidndashpolymerhybridnanoparticles
AT somanis regressionofmelanomafollowingintravenousinjectionofplumbaginentrappedintransferrinconjugatedlipidndashpolymerhybridnanoparticles
AT laskarp regressionofmelanomafollowingintravenousinjectionofplumbaginentrappedintransferrinconjugatedlipidndashpolymerhybridnanoparticles
AT mullinm regressionofmelanomafollowingintravenousinjectionofplumbaginentrappedintransferrinconjugatedlipidndashpolymerhybridnanoparticles
AT dufesc regressionofmelanomafollowingintravenousinjectionofplumbaginentrappedintransferrinconjugatedlipidndashpolymerhybridnanoparticles
_version_ 1718389476450893824

Ejemplares similares